

Appl. No. : 10/606,162
Filed : June 25, 2003

REMARKS

Restriction to one of the following groups was required under 35 USC 121:

- Group I Claims 1-29, drawn to a method of determining the activation state of a cell by determining the equilibrium between its kinase and phosphatase activities, using capture molecules on a solid support to stabilize and characterize kinase/phosphatase target proteins, classified in class 435, subclass 7.1;
- Group II Claims 30-32, drawn to a kit for evaluation of an activation level of a cell by quantification of a level of phosphorylation of multiple specific cellular proteins, a kit which includes solutions with detection molecules and a support with capture molecules, classified in class 436, subclass 63;
- Group III Claims 33-36, drawn to a support comprising at least five of a group of named capture molecules, classified in class 435, subclass 287.1.

In response to this Restriction Requirement, Applicant elects Group I that is claims 1-29.

Election of Species

Additionally, the Applicant was required to elect one combination of proteins that may consist of at least three candidates from Table 1 (serine/threonine kinases), at least three candidates from Table 2 (tyrosine kinases), at least 3 candidates from Table 3 (transcription factors), **OR** at least three candidates from the list Cyclin A, Cyclin B, Cyclin D1, Cyclin D3, Cyclin E, CDK1, CDK2, CDK4, CDK6, E2F, CDC2, cdc25c, Cdc25A, Chk2, Chk1, pRb, p53, p21, p27, and Wee1, **OR** a specific combination of any of the above alternatives, for further examination on the merits. In response to this restriction requirement, Applicant elects species of MKK3 / PAK6 / CDK8 in claim 15. The Examiner further required electing one species among types of treatment recited in Claim 27. Applicant elects the species of chemical treatment.

Applicant understands that upon allowance of a generic claim, Applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. Currently, Claim 1 is generic to the dependent Claims 15-21 and 27.

Appl. No. : **10/606,162**
Filed : **June 25, 2003**


Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: April 26, 2006

By: _____


Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5586

2551415
042506